New drug zuberitamab takes on kidney disease in Head-to-Head trial
NCT ID NCT06642909
First seen Nov 20, 2025 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a new medicine, zuberitamab, against a standard treatment (cyclosporine) in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. The goal is to see if zuberitamab can better reduce protein in urine over 76 weeks, while checking for side effects. Participants must be 18-75 and have a confirmed diagnosis by kidney biopsy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.